Glaxo-smith-kline-presentation.

13,948
-1

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
13,948
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
694
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Glaxo-smith-kline-presentation.

  1. 1. Glaxo Smith Kline<br />
  2. 2. GSK’S Introduction<br />GlaxoSmithKline often abbreviated to GSK, is a global<br /> pharmaceutical, biologics, vaccines and consumer<br /> healthcare company headquartered in London, United<br /> Kingdom.<br />
  3. 3. GSK’S Introduction<br />It is world’s third largest pharmaceutical company measured by revenues ( after Johnson and Johnson and Pfizer.<br />It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. <br />
  4. 4. History<br /><ul><li> GlaxoSmithKline plc is a public limited company incorporated on 6th December 1999 under English law. Its shares are listed on the London Stock Exchange and the New York Stock Exchange.
  5. 5. On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline Beecham plc, both English public limited companies, by way of a scheme of arrangement for the merger of the two companies.</li></li></ul><li>History<br /> GSK and its subsidiary and associated undertakings constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.<br />GSK has its corporate head office in London and has its US headquarters in Research Triangle Park, North Carolina, with operations in some 120 countries, and products sold in over<br /> 150 countries.<br />
  6. 6. Chairman:<br /> Sir Christopher Gent<br />Chief Executive Officer:<br /> Andrew Witty<br />
  7. 7. GSK’s Mission<br />GSK MISSION<br />GROW<br />MISSION<br />SIMPLYFY<br />DELIVER<br />
  8. 8. GSK’S Mission<br /><ul><li> Grow a diversified global business – We are diversifying our business to create a more balanced product portfolio and move away from a reliance on traditional ‘white pill/western markets’. We are investing in key growth areas such as Emerging Markets, Japan, Vaccines and our Consumer Healthcare business.</li></ul>.<br />
  9. 9. GSK’S Mission<br /><ul><li>Deliver more products of value – We aim to sustain an</li></ul> industry-leading pipeline of products, ensuring that they<br /> demonstrate value for healthcare providers. Our R&D<br /> strategy is built around focusing on the best science,<br /> diversifying through externalisation of research, and <br /> improving the returns on investment.<br />
  10. 10. GSK’S Mission<br /><ul><li>Simplify the operating model – GSK is a large and complex organisation. We are transforming our operating model to reduce complexities, improve efficiency and reduce costs</li></li></ul><li>Products <br />Prescription medicines<br />Vaccines<br />Consumer Healthcare<br />
  11. 11. PRESCRIPTION MEDICINES<br />
  12. 12. ALLI-WEIGHT LOSS DRUG<br />
  13. 13. AVANDIA-DIABETIS CONTROL<br />
  14. 14. ROTAVIRUS VACCINE ROTARIX<br />
  15. 15. VACCINE FOR MEASLES<br />
  16. 16. CONSUMER HEALTHCARE PRODUCTS<br />
  17. 17. CONSUMER HEALTHCARE PRODUCTS<br />
  18. 18. Two other companies<br />Stiefel, a GSK company— A Global Leader in Dermatology<br />ViiV Healthcare —<br /> a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people <br />
  19. 19. STIEFEL-A GSK COMPANY<br />
  20. 20. VIIV- HEALTHCARE COMPANY<br />
  21. 21. Turnover ( in billion pounds)<br />2009 28.4<br />2008 24.4<br />2007 22.7<br />2006 23.2<br />2005 21.7<br />
  22. 22. World market by geographic region<br /> value(billion pounds) % of total<br />USA 187 40<br />Europe 131 28<br />France 25 5<br />Germany 24 5<br />Italy 16 3<br />UK 12 3<br />Rest of World 150 32<br />Emerging markets 66 14<br />Asia Pacific 20 4<br />Japan 50 11<br />Canada 11 2<br />
  23. 23. Regional analysis <br /> (2009) (2008) cer% pnd%<br />USA 9,180 8,894 (13) 3<br />Europe 7,681 6,483 9 18<br />Emerging Markets 2,973 2,290 20 30<br />Asia Pacific/Japan 2,700 1,918 16 41<br />Other trading‡ 1,180 796 31 48<br /> 23,714 20,381 2 16<br />
  24. 24. CER% represents growth at constant exchange rates.<br />Pound % growth at actual exchange rates.<br />
  25. 25. Consumer Healthcare turnover(million pounds)<br /> (2009) (2008) cer% pound %<br />Over the counter 2,319 1935 8 20<br />Medicines<br />Oral healthcare 1484 1240 7 20<br />Nutritional healthcare 851 796 3 7<br />
  26. 26. Sales Trend<br />
  27. 27. Five countries chosen<br /><ul><li>USA
  28. 28. JAPAN
  29. 29. GERMANY
  30. 30. SWITZERLAND
  31. 31. UK</li></li></ul><li>COMPETITORS IN USA<br /> NAME OF THE COMPANY<br />Johnson & Johnson<br />Abbott Laboratories<br />Merck & Co.<br /> Eli lilly<br />Bristol-Myers Squibb<br />TOTAL REVENUE(IN USD BILLIONS )<br />61.90<br />30.76 <br /> 27.43<br />21.84<br />18.81<br />
  32. 32. JOHNSON &JOHNSON<br />
  33. 33. ABBOT LABORATARIES<br />
  34. 34. MERCK &CO.<br />
  35. 35. ELI LILLY<br />
  36. 36. BRISTOL-MYERS SQUIBB<br />
  37. 37. COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL.<br />ASTELLAS PHARMA<br />DAIICHI SANKYO 9<br />EISAI<br />CHUGAI PHARMACEUTICAL .<br /> TOTAL REVENUE<br /> (IN USD BILLIONS)<br />15.6<br />10.7<br />9<br />5.5<br />2.0<br />
  38. 38. TAKEDA PHARMACEUTICALS<br />
  39. 39. ASTELLAS PHARMA<br />
  40. 40. DAIICHI SANKYO<br />
  41. 41. EISAI<br />
  42. 42. CHUGAI PHARMACEUTICALS<br />
  43. 43. COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br /> TOTAL REVENUE<br /> (IN USD BILLIONS)<br />22.3<br />16.9<br />5.17<br />
  44. 44. BAYER<br />
  45. 45. BOEHRINGER INGELHEIM<br />
  46. 46. MERCK KGAA<br />
  47. 47. COMPETITORS IN SWITZERLAND<br />NAME OF THE COUNTRY<br />HOFFMAN LA ROCHE<br />NOVARTIS<br />NYCOMED<br /> TOTAL REVENUE<br /> (IN USD BILLIONS)<br />47.35<br />44.27<br />4.26<br />
  48. 48. HOFFMAN LA ROCHE<br />
  49. 49. NOVARTIS<br />
  50. 50. NYCOMED<br />
  51. 51. COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />45.83<br />32.81<br />GlaxoSmithKline<br />AstraZeneca<br />
  52. 52. ASTRA ZENECA<br />
  53. 53. SUBMITTED BY:<br />ISHDEEP SINGH<br />M100700019<br />

×